Heptachlor Epoxide Critical Evaluation by Wandji, Serge-Alain et al.
Cornell University
Program on Breast Cancer and Environmental
Risk Factors in New York State (BCERF)*
     Critical Evaluation # 3
October, 1998
Critical Evaluation of
Heptachlor and Heptachlor Epoxide’s
Breast Cancer Risk
by
Serge-Alain Wandji, Ph.D., Renu Gandhi, Ph.D.
and Suzanne M. Snedeker, Ph.D.**
*The institutional home of BCERF is the
Institute for Comparative and Environmental Toxicology (ICET)
in the Cornell Center for the Environment
** Address correspondence to: Supported by grants from:
Dr. Suzanne M. Snedeker New York State Dept. of Health




Fax:  (607) 255-8207
e-mail:  sms31@cornell.edu
This report  is posted on the BCERF web-page at: <http://www.cfe.cornell.edu/bcerf/>.
Permission may be requested to reproduce the final report, without alteration of text or tables, as
long as credit is given to the authors, BCERF and Cornell University.
BCERF
Table of Contents-Heptachlor and Heptachlor Epoxide Critical Evaluation
Title Page ..................................................................................................................................................................... i
Table of Contents ......................................................................................................................................................... ii
List of Tables ................................................................................................................................................................ iv
I. Chemical Information ......................................................................................................................................... 1
A. Common Name ......................................................................................................................................... 1
B. Chemical Name for Heptachlor ................................................................................................................. 1
C. Chemical Formula for Heptachlor ............................................................................................................. 1
D. Trade Names for Heptachlor ..................................................................................................................... 1
E. Chemical Structure of Heptachlor ............................................................................................................. 1
F. CAS Registry Number for Heptachlor ....................................................................................................... 1
G. Major Metabolite:  Heptachlor Epoxide .................................................................................................... 1
H. Chemical Name for Heptachlor Epoxide ................................................................................................... 1
I. Trade Name for Heptachlor Epoxide .......................................................................................................... 1
J. Chemical Formula for Heptachlor Epoxide ................................................................................................ 1
K. CAS Registry Number for Heptachlor Epoxide ........................................................................................ 1
L. Chemical Structure of Heptachlor Epoxide ............................................................................................... 1
II. History of Use, Usage and Nomenclature .......................................................................................................... 1
III. Current Regulatory Status ...................................................................................................................................2
A. Regulatory Status ...................................................................................................................................... 2
1. EPA ............................................................................................................................................... 2
2. NYS DEC ..................................................................................................................................... 2
B. Drinking Water Standards and Health Advisories ..................................................................................... 2
C. Food Residue Tolerances and Action Levels ............................................................................................. 3
D. Acceptable Daily Intake ............................................................................................................................ 3
E. Workplace Regulations .............................................................................................................................. 3
IV. Summary of Evidence of Overall Carcinogenicity (non-breast sites) .................................................................3
A.  Human Studies ......................................................................................................................................... 3
1. Case-Reports  ............................................................................................................................... 3
2. Case-Control Studies .................................................................................................................... 3
3. Cancer Mortality Occupational Cohort Studies ........................................................................... 3
a. Manufacturing Plants ..................................................................................................... 3
b. Pesticide Applicators ...................................................................................................... 4
4. Summary, Human Studies (non-breast sites) ............................................................................... 5
B.  Experimental Animal Studies ................................................................................................................... 5
1. Mice ............................................................................................................................................. 5
2. Rats .............................................................................................................................................. 6
3. Summary, Animal Studies (non-mammary sites) ......................................................................... 7
C.  Current Classification of Carcinogenicity by Other Agencies .................................................................. 7
1. IARC Classification ..................................................................................................................... 7
2. NTP Classification .......................................................................................................................... 7
3. EPA Classification .......................................................................................................................... 7
V. Critical Evaluation of Breast Carcinogenicity ....................................................................................................... 7
A. Human Studies ............................................................................................................................................. 7
1. Adipose Tissue Levels .................................................................................................................... 7
2.  Cow’s Milk and Human Breast Milk Levels ................................................................................. 8
3.  Case-Control Studies ..................................................................................................................... 9
B.  Animal Studies ......................................................................................................................................... 11
C.  Other Relevant Data on Breast Cancer Risk ............................................................................................. 11
ii Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State
1. Immunological Effects ............................................................................................................................... 11
2. Mutagenicity .............................................................................................................................................. 11
3. Evidence of Tumor Promotion ................................................................................................................... 11
4. Signal Transduction and Intercellular Communication .............................................................................. 11
5. Disruption of the Endocrine System .......................................................................................................... 11
a.  Effects on Hepatic Microsomal Hydroxylases ............................................................................ 12
b. Evidence of Estrogenicity ............................................................................................................ 12
c. Effects on Reproduction ............................................................................................................... 12
VI. Other Relevant Information .............................................................................................................................................. 13
A. Environmental Fate and Potential for Human Exposure ......................................................................................... 13
VII. Summary and Recommendations for Classification ......................................................................................................... 15
A. Breast Cancer Risk Classification ........................................................................................................................... 15
VIII. Research Gaps and Other Recommendations.................................................................................................................... 15
IX. Summary of Human Studies Currently Being Conducted................................................................................................. 16
X. Bibliography...................................................................................................................................................................... 17
XI. Appendix A. Common Abbreviations, Acronyms and Symbols........................................................................................ 22
XII. Appendix B. Critical Evaluations of Breast Cancer Risk  ................................................................................................ 23
Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State iii
List of Tables
Table 1.  Breast adipose tissue concentrations (ppm) of heptachlor epoxide residues in women with breast cancer (cases) or women
without breast cancer (controls)
Cornell University Program on Breast Cancer and Environmental Risk Factors in New York Stateiv
Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State 1
Critical Evaluation of Heptachlor and Heptachlor Epoxide’s
Breast  Cancer Risk
Authors’ Note:  A separate Critical Evaluation had been prepared on chlordane and chlordane metabolites.  The reader is encouraged
to read the attached document, Appendix B which includes an explanation of the BCERF Breast Cancer Risk Classification System,
before reading this Critical Evaluation.
I.  Chemical Information:
A. Common Name:  Heptachlor (IARC, 1991)
B. Chemical Name for Heptachlor:  1,4,5,6,7,8,8-heptachloro-
3a,4,7,7a-tetrahydro-4,7-methanoindene (IUPAC) (IARC, 1991)
C. Chemical Formula for Heptachlor:  C10H5Cl7 (Montgomery,
1993)
D. Trade Names for Heptachlor:  Biarbinex®, Cupincida®,
Fennotox® (Velsicol Chemical Co.); Vegfru Heptox® (Pesticides
India); Drinox®; H-34, Heptamul®; Heptox® (Savriti Pesticides
& Agrochem Ltd.) (Meister, 1996)
E. Chemical Structure of Heptachlor:   (IARC, 1991)
F. CAS Registry Number for Heptachlor:   76-44-8 (replaced
CAS registry numbers:  23720-59-4; 37229-06-4) (IARC,
1991)
G. Major Metabolite:  Heptachlor epoxide
Heptachlor epoxide is the oxidation product of heptachlor
(Worthing, 1991).
H. Chemical Name for Heptachlor Epoxide:  1,4,5,6,7,8,8-
heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro-4,7-methanoindene
(IUPAC) (IARC, 1991)
I. Trade Name for Heptachlor Epoxide:  Velsicol 53-CS-17
(Velsicol Chemical Co.) (ATSDR, 1993)
J. Chemical Formula for Heptachlor Epoxide : C10H5Cl7O
(IARC, 1991)
K. CAS Registry Number for Heptachlor Epoxide  1024-57-3
(replaced CAS registry numbers: 4067-30-5; 24699-42-1;24717-
72-4; 28044-82-8; 66240-71-9) (IARC, 1991)
L. Chemical Structure of Heptachlor Epoxide:  (IARC, 1991)
II.  History of Use , Usage and  Nomenclature:
Heptachlor is a persistent, non-systemic, chlorinated hydrocarbon
insecticide (ATSDR, 1993; Worthing, 1991).  Heptachlor is a
member of the cyclodiene class of insecticides which includes
the structurally similar insecticides aldrin, isoaldrin, dieldrin,
endrin, chlordane, isobenzan and [alpha] endosulfan (Smith,
1991c).  Technical-grade heptachlor is a mixture of several
chemicals, and contains about 72% heptachlor and 28% related
compounds, including 20-22% gamma chlordane, and 4-8%
gamma nonachlor.  Heptachlor is also one of the components of
technical-grade chlordane (approximately 10-20% heptachlor by
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weight) (IARC, 1991).  One of the predominant isomers in
technical chlordane, trans-chlordane, can be metabolized to
heptachlor.  The major breakdown product of heptachlor is its
oxidized form, heptachlor epoxide, a persistent environmental
contaminant (ATSDR, 1993; IARC, 1991).
Heptachlor was introduced in the US in 1952, and was used to
treat soil and to protect field corn, seed (for corn, wheat, oat,
barley and sorghum), bulbs, citrus fruits and pineapple from insect
pests.  It was used as an insecticide to control ants, cutworms,
maggots, termites, thrips (wingless insect pest), weevils,
wireworms, grasshoppers and mosquitoes to prevent insect
damage to agricultural crops.  In the mid-1960s heptachlor was
recommended as an insecticide to control grubs and ants in
turfgrass at the rate of 2 pounds (lbs) and 5 lbs per acre,
respectively (Weidhass et al., 1966).  Heptachlor was also used to
protect buildings, homes, lawns and gardens from soil insects and
termites, and for control of fire ants in power transformers
(ATSDR, 1993; Kutz et al., 1991a; Smith, 1991a; Worthing, 1991).
It has also been used in the processing of termite-resistant plywood
in Europe (Mussalo-Rauhamaa et al., 1988). In 1974, 2 million
lbs of heptachlor was used in the US, with 75% used in agriculture,
mostly for corn soil treatment (EPA, 1976).  The distribution of
heptachlor use in the 1974 was:  58% corn, 27% pest control,
13% to treat seeds, 2% for various uses, including fire ant control,
and use on fruit crops (citrus and pineapples) (IARC, 1979). No
current information could be located on the production,
importation or exportation levels of heptachlor in the US.
Special note on heptachlor use in New York State.
In New York State (NYS), heptachlor use was restricted to
incorporation into baits to control the alfalfa snout beetle.
Heptachlor was not allowed for use as a termiticide in NYS.
However, technical chlordane, which is 10-20% heptachlor
(IARC, 1991) was used to control insects on turf and agricultural
crops up to 1975, and was heavily used in downstate NYS as a
termiticide until 1985 (NYSDEC, 1986).
III.  Current Regulatory Status:
A.  Regulatory Status:
1. EPA:  In 1974, because of risk of carcinogenicity as determined
from animal cancer bioassays; detection of heptachlor epoxide in
dairy, meat, fish, and poultry products; and the persistence and
bioaccumulation of heptachlor, the EPA recommended cancelling
nearly all registered uses of this insecticide (ATSDR, 1993;
USEPA, 1990).  A letter from Russell E. Train, Administrator of
the Velsicol Chemical Corp., the main manufacturer and registrant
of heptachlor and chlordane, announced the “Intent to Cancel
Registrations of Certain Pesticide Products Containing Heptachlor
or Chlordane” in December of 1975.  A series of documents
clarifying the original letter was published in the Federal Register
in February of 1976 (EPA, 1976).  Some limited agricultural uses
of heptachlor as a seed treatment, against the narcissus bulb fly,
and on pineapple against mealybug wilt, was recommended in
the 1976 documents (EPA, 1976). These agricultural uses of
heptachlor were gradually phased out over a five year period
ending on July 1, 1983 (ATSDR, 1993).  In 1983, certain uses
were exempted from EPA’s 1983 cancellation, including use of
heptachlor for control of termites in underground areas, fire ant
control in buried cable closures, and dipping of roots or tops of
nonfood plants.  All other uses of heptachlor were either
voluntarily cancelled by the manufacturer, Velsicol Chemical Co.,
or were suspended for failure to meet EPA requirements.  Effective
as of April 15, 1988, the sale, distribution and shipment of
heptachlor products was prohibited in the US.  Commercial use
of existing stocks of heptachlor products was also prohibited,
except for fire ant control in power transformers.  Domestic use
of existing stocks of chlordane and heptachlor products that are
in the possession of homeowners is also permitted by the EPA
(ATSDR, 1993; USEPA, 1990).
2. NYS DEC:  All use of both heptachlor and chlordane in NYS
was prohibited on March 13, 1985 by emergency action as
mandated by the NYS DEC (NYSDEC, 1986).
B.  Drinking Water Standards and Health Advisories:
The EPA has set a Maximum Contaminant Level (MCL) for
heptachlor in drinking water at 0.0004 mg/L, and the MCL for
heptachlor epoxide is 0.0002 mg/L (USEPA, 1996).  The MCL is
an enforceable limit on the maximum allowable concentration of
a chemical in public water supplies.  Health Advisory* (HA) levels
for heptachlor and heptachlor epoxide in drinking water as are
follows (USEPA, 1996):
Heptachlor:
      10 kg child:
•  One day  = 0.01 mg/L
•  Longer-term = 0.0001 mg/L
      70 kg adult
•  Longer term = 0.0001 mg/L
Heptachlor epoxide:
      10 kg child:
•  One day  = 0.01 mg/L
•  Longer-term = 0.0001 mg/L
      70 kg adult
•  Longer term = 0.0001 mg/L
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*The HAs are nonenforceable limits of the concentration of a
chemical in drinking water that are not expected to cause any
adverse noncarcinogenic health effects when consumed for up to
the time period specified, with a margin of safety (USEPA, 1996).
C. Food Residue Tolerances and Action Levels:
The Food and Drug Administration (FDA) and the US Department
of Agriculture (USDA) are responsible for monitoring the levels
of heptachlor and heptachlor epoxide residues in domestic and
imported foods, and animal feed.  The EPA sets tolerances (the
maximum amount of a residue that is permitted in or on the food).
Because heptachlor and heptachlor epoxide are possible
carcinogens, the tolerance for heptachlor and heptachlor epoxide
residues in foods has been set at zero. Since heptachlor and
heptachlor epoxide persist in soil, the FDA established action
levels for unavoidable residues of these chemicals in raw
agriculture products.  These action levels represent limits at or
above which the FDA can take legal action to remove these
commodities from the market place.  The action levels for
heptachlor and heptachlor epoxide range from 0.01 to 0.02 ppm
in raw vegetables, raw fruits, grains, eggs, nuts, and sugarcane;
0.01 ppm for processed animal fed, fodder and hay; 0.1 ppm for
milk on a fat basis; 0.2 ppm in the fat portion of rabbits; and 0.3
ppm for the edible portion of fish (FDA,1994).
D. Acceptable Daily Intake:
The acceptable daily intake (ADI) of heptachlor and heptachlor
epoxide from food set by the World Health Organization (WHO)
is 0.1 µg/kg/day (WHO, 1993)
E. Workplace Regulations:
The Occupational Health and Safety Administration (OSHA) has
set limits on workplace exposures to heptachlor.  OSHA
recommends that the maximum level of heptachlor in workplace
air for an 8-hour day for a 40-hour work week not exceed 0.5 mg/
m3 (ATSDR, 1993).
IV.  Summary of Evidence of Overall
       Carcinogenicity (non-breast sites):
A. Human Studies:
1. Case-Reports:
Although case-reports are not sufficient to demonstrate the
carcinogenicity of chemicals, they may provide useful information
to justify the need for further epidemiological studies.
In one case report, a woman who drank cow’s milk contaminated
with heptachlor during her pregnancy gave birth to a boy
diagnosed at seven weeks of age with a relatively rare brain tumor,
a gliosarcoma.  Chromosomal abnormalities were found in a tissue
culture of the tumor, but the peripheral blood displayed normal
karotyping.  The authors of the case-report concluded that
heptachlor could not be implicated as the causal factor in the
development of the tumor, and the occurrence of the sarcoma
was considered to be spontaneous (Chadduck et al., 1987).
Two reports have described cases of leukemia diagnoses after
exposure to chlordane/heptachlor in domestic settings.  In the first
report, Infante et al. (1978) described three cases of leukemia,
two of which were associated with exposure to chlordane or
heptachlor and one in which exposures to other chemicals
including 2,4-D and diazinon were also reported.  Epstein and
Ozonoff (1987) reported five other cases of leukemia associated
with chlordane and heptachlor exposure.  In three of these cases,
the exposure was limited to chlordane and heptachlor, and in the
other two cases, the patients were exposed to other chemicals as
well, including Telodrin, and malathion.
These case-reports are based on self-reported exposures, lack a
complete medical history of the individuals and do not provide
the details on the formulation of chlordane/ heptachlor applied or
the duration or extent of exposure.  In addition, none of the studies
provided an estimate of the expected number of leukemia cases
in absence of exposure to chlordane and heptachlor.  Consequently,
these studies do not provide a good basis to assess the role of
heptachlor in affecting the incidence of leukemia in humans.
2. Case-Control Studies:
One case-control study conducted on male agricultural workers
in Iowa and Minnesota, has evaluated the risk of leukemia in
workers who handled, mixed or applied heptachlor (Brown et al.,
1990).  Information on residential history, drinking water sources,
nonfarm occupational history, smoking and alcohol use, family
history of cancer, and farm activities were obtained by
questionnaire.  The risk of developing leukemia was not elevated
(Odds Ratio [OR] = 0.9; 95% Confidence Interval [CI] 0.5-1.7)
in 14 male agricultural workers who handled, mixed or applied
heptachlor compared to 43 controls who had never worked as
farmers. There also was no increased risk of leukemia in the
agricultural workers who had handled chlordane (OR=0.7; 95%
CI  0.3-1.16).  There was no mention if nonagricultural usage of
heptachlor was controlled for in cases and controls.  The ORs
were adjusted for confounding factors, including age, state,
tobacco use, family history of lymphopoietic cancer, and exposure
to substances (benzene, napththa, hair dyes) related to the risk of
leukemia (Brown et al., 1990).
3. Cancer Mortality Occupational Cohort Studies:
a. Manufacturing Plants:
Three industry-funded cohort studies have examined the
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association between occupational exposure to heptachlor and the
risks of cancer mortality among workers employed at a heptachlor/
endrin manufacturing plant.  The findings of these studies are
summarized below.
In a retrospective cohort study, Wang and MacMahon (1979)
examined the causes of mortality in a cohort of 1,403 white male
workers employed for at least three months at two plants
manufacturing either chlordane (plant 1) or heptachlor and endrin
(plant 2).  A total of 835 workers in the heptachlor/endrin plant
were followed from 1952 to 1976.  Expected deaths were
calculated on the basis of national rates.  Standardized Mortality
Ratios (SMR) were computed by dividing the observed deaths
by the expected values.  A small but nonsignificant excess of deaths
from all cancers (SMR 1.21; 95% CI  not given) was observed at
plant 2.  Excess deaths from lung cancer was higher at plant 2
(SMR 1.74) compared to the plant 1 (SMR=1.15), but  was not
statistically significant.  The combined SMR for lung cancer
mortality at both plants was much higher (7 observed, 2.6
expected, p < 0.01) for men who were under age 35 at the
beginning of employment.
However, because of the limited number of individuals followed,
it was not possible to determine whether the number of lung cancer
deaths increased as a function of duration of follow-up or duration
of employment.  The validity of the study is further limited by the
lack of complete occupational history for each worker and hence
a history of previous chemical exposures, and lack of consideration
of confounding factors, such as smoking history that may have
affected the results of this study.  In addition, workers at plant 2
were also exposed to other chemicals, including chlorine, vinyl
chlorine, chlorendic anhydride and hexachlorocyclopentadiene.
Therefore, exposure to these other chemicals may have played a
role in the induction of employment-related cancers.  Causes of
mortality were not analyzed among the 68 female workers
employed at both manufacturing plants.
A second cohort study reported by Ditraglia, et al. (1981) examined
the mortality rates from cancer among 305 white males recruited
between 1951 and 1964 who were employed for at least 6 months
at the same plant 2 as described previously (Wang and MacMahon,
1979).  This cohort was followed from 1951 or 1964 to 1976.
There was no excess mortality from all cancers (SMR=0.91; 95%
CI  0.3-1.98) and the authors commented that this low SMR may
reflect a “healthy worker effect.”  There was a slight, but
statistically nonsignificant increase for respiratory cancer deaths
at plant 2 (SMR=1.22; 95% CI  0.25-3.58).  The relationship
between cancer mortality and numbers of years since date of first
employment was also determined.  There was a deficit of deaths
from all cancers in those employed for 10 to 19 years
(SMR= 0.91; 95% CI  0.18-2.66), while there was a higher risk
of cancer deaths in those employed for ≥ 20 years (SMR=1.62;
95% CI  0.33-4.74) at the heptachlor/endrin plant.  While neither
observation was statistically significant, the size of the sample
may not have been sufficiently large to detect statistical differences
(Ditraglia et al., 1981) .
This cohort was followed at plant 2 for an additional 11 years by
Brown (Brown, 1992).  No excess cancer mortality was reported
(SMR=1.0; 95% CI  0.6-1.59).  There was a nonsignificant deficit
of deaths from respiratory cancer (SMR=0.88; 95% CI  0.32-1.92)
and intestinal cancer (SMR=0.63; 95% CI  0.02-3.53).  Mortality
from stomach cancer (SMR=2.84; 95% CI  0.43-10.27) was
elevated, but it was not statistically significant, while mortality
from bladder cancer was significantly elevated (SMR=7.12; 95%
CI  1.47-20.84).  The authors recognized that survival of bladder
cancer has improved and consequently, a better estimate of the
true risk would have been determined from incident cases rather
than deaths.  The strength of evidence of the carcinogenicity of
heptachlor in both the original (Ditraglia et al., 1981) and the
updated follow-up (Brown, 1992) studies is limited because death
rates from specific types of cancer were not analyzed as a function
of latency, and exposure data on heptachlor were not provided.
Risk analyses in these studies also carry over the confounding
effects of co-exposure to endrin, chlorine, vinyl chloride,
chlorendic anhydride and hexachlorocyclopentadiene.
In summary, with the exception of bladder cancer, mortality from
all neoplasms among workers employed at the heptachlor plant
in Memphis, TN, was comparable to that of the general US
population.  A small but  nonsignificant excess mortality from
lung cancer was reported in three of the studies (Ditraglia et al.,
1981; Wang and MacMahon, 1979; Brown, 1992).  A significant
excess of deaths from bladder cancer based on a small number of
cases was reported by one investigator (Brown, 1992).  All three
studies were conducted at the same manufacturing plant and
consequently, do not provide independent estimates of cancer risk.
The validity of these studies was also limited because the number
of individuals enrolled was small (835 for Wang and MacMahon,
1979; and 305 for Ditraglia et al., 1981 and Brown, 1992).
Moreover, it is difficult to attribute specifically the reported cancer
deaths to heptachlor because the workers were also exposed to
many other chemicals.  There is also an inherent difficulty in
interpreting occupational exposures and cancer mortality data.
Because of long latency periods from the exposures to
development of neoplasms, cancer may not develop in those
occupationally exposed to suspect chemicals until after retirement
or a change in employment.
b. Pesticide Applicators:
The association between exposure to heptachlor and risk of cancer
mortality has also been studied among pesticides applicators.  An
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18 year long follow-up cohort study of mortality causes among
16,124 urban pesticide applicators (MacMahon et al., 1988) found
a significant  excess of deaths from lung cancer among non-termite
control operators (SMR=1.58; 95% CI  1.29-1.90) but not among
the group of workers who had the higher probability of exposure
to chlordane and heptachlor (SMR=0.97; no 95% CI  given).  This
study did not provide individual exposure data and the pesticide
applicators were exposed to varying amounts of other chemicals
as well.  This study did not control for tobacco use among the
pesticide applicators, and patterns of tobacco use may have
contributed to the incidence of lung cancer deaths in this cohort.
A study of mortality causes among 3,827 white male pesticide
applicators in Florida (Blair et al., 1983) reported a nonsignifi-
cant excess of deaths from lung cancer (SMR=1.35; 95% CI  not
given).    A moderate, but nonsignificant excess in mortality from
lung cancer (SMR=1.35) and brain cancer (SMR=2.00) was ob-
served among workers employed by firms licensed for termite
treatment.  The risk of mortality from lung cancer rose with the
number of years licensed with an SMR of 1.01 among those li-
censed for less than 10 years, compared with a SMR of 2.89
(p<0.05) for those licensed for more than 20 years.  Unfortunately,
since use of tobacco products was not controlled for in this study,
conclusions can not be made about the relationship between
estimates of exposure to pesticides and lung cancer mortality.  The
termite applicators were also licensed to use  other organochlorine
pesticides such as aldrin, DDT, chlordane, propuxur and
chlorpyrifos, hence co-exposures to these chemicals were likely.
There were only 11 deaths observed among the 1,638 white
women pesticide applicators, and the authors stated that there were
too few deaths for statistical analysis to determine risk of cancer
mortality.
4. Summary, Human Studies (non-breast sites):
An isolated case report of a gliosarcoma has been reported in a
child born to a mother who ingested heptachlor-contaminated milk
during her pregnancy, but no causal relationship could be
established (Chadduck et al., 1987).  While there have been several
case-reports of leukemia in chlordane / heptachlor exposed
individuals (Epstein and Ozonoff, 1987; Infante et al., 1978), a
small case-control comparison of agricultural workers exposed
to heptachlor or chlordane failed to find an increased risk of
leukemia (Brown et al., 1990).  A significant increase in risk of
death from lung cancer was reported among termite control
applicators who had been licensed for at least 20 years (Blair et
al., 1983).  However, this study did not control for the use of
tobacco products, and the evidence that occupational exposure to
heptachlor increases the risk of death from lung cancer is not
supported by the results of other studies (Brown, 1992; MacMahon
et al., 1988; Ditraglia et al., 1981; Wang and MacMahon, 1979a).
A significant increase in deaths from bladder cancer was reported
among workers at the heptachlor manufacturing plant (Brown,
1992) but the excess mortality from this type of cancer was not
statistically significant among termite applicators (Blair et al.,
1983).  It is difficult to specifically attribute any excess of cancer
deaths to heptachlor because in all these studies workers and
pesticide applicators were exposed to other chemicals as well.
Other confounding factors, such as smoking history, were not
controlled for in these studies.  Consequently, these cohort studies
provide insufficient  evidence to determine whether or not
exposure to heptachlor imparts a significant risk for cancer in
humans.
Finally, these studies have not examined mortality causes among
women employed by the heptachlor manufacturing plant or firms
licensed for pesticide application.  Therefore, there are no reported
data available on occupational exposure to heptachlor in women
and cancer mortality.  Wives of heptachlor manufacturing workers
and applicators may have been exposed to heptachlor and
heptachlor epoxide by handling contaminated clothing during
laundering of spouse’s work clothes, but there have been no studies
that have evaluated cancer incidence or mortality in wives of
workers who may have been exposed to heptachlor.
B. Experimental Animal Studies:
Selected histological materials from previous unpublished and
published long-term studies on heptachlor’s oncogenicity in
rodents have been reviewed by a panel of pathologists from the
National Academy of Science (NAS) (IARC, 1991).  Some of
these studies are reported here.
1. Mice:
Epstein (1976) reported on a 1965 unpublished FDA study in
which 100 C3H mice of each sex were fed 0 or 10 ppm of
heptachlor or heptachlor epoxide for 24 months. A review panel
of pathologists from the NAS concluded that there was a
significant increase in the incidence of hepatocellular carcinomas
in females but not in males given heptachlor, whereas heptachlor
epoxide caused liver carcinomas in both male and female mice
(IARC, 1991).  The study is of limited value because the mortality
rate was markedly elevated in heptachlor (70%) and heptachlor
epoxide (90.5%) treated groups and consequently, few animals
survived for the evaluation of the treatment effects.  Epstein, in
his review of the FDA study, noted that premature death was
particularly high in animals fed heptachlor epoxide, but no data
were available on time of unscheduled deaths or tumor detection
in either control or treated groups (Epstein, 1976).  The high
mortality rate among the controls (66%) raises the possibility that
the mice were also dying from causes unrelated to heptachlor or
heptachlor epoxide.  In addition, the purity of the heptachlor and
heptachlor epoxide preparations was not specified, therefore, the
actual concentration of these insecticides, and level of other
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contaminates or metabolites in the diets,  is uncertain.  This study
also only administered one treatment dose to the animals.  Multiple
doses should have been administered so a dose-response effect
could have been evaluated.
Epstein also reported the results of an unpublished cancer bioassay
conducted by the International Research and Development
Corporation (IRDC) for the Velsicol Chemical Corporation in
1973 (Epstein, 1976).  Charles River CD-1 mice, 100 of each
sex, were fed a mixture of 75% heptachlor epoxide and 25%
heptachlor (purity not specified) at 0, 1.0, 5.0 and 10.0 ppm starting
at 7 weeks of age for 18 months.  At six months, 10 animals from
each test and control group were killed for the preparation of
histology samples from the liver.  Mortality rates for the remaining
animals by 18 months were high, ranging from 34 to 49% in the
1 and 5 ppm groups, and 71% and 70% in the female and male
high dose 10 ppm groups, respectively.  The usefulness of the
results of this study is severely limited, because of the high
mortality rate, and in addition, a large numbers of tissues from
animals that died during the study were lost to autolysis, and could
not be evaluated histopathogically.  Epstein notes that this autolysis
probably resulted in an underestimate of the incidence of liver
tumors. Also, there was no evidence that the organs of the animals
sacrificed at 18 months and that died during the study were
examined or evaluated “blindly ”(Epstein, 1976).
Since the original IRCD report was vague as to the carcinogenicity
or non-carcinogenicity of the heptachlor/heptachlor epoxide
mixture, the histological material from the IRDC study was
subsequently reevaluated by a NAS panel in 1977.  The results of
the NAS panel review has been summarized by others (IARC,
1991).  The NAS panel concluded that there was a significant
(p<0.01) increase in the combined incidence of hepatocellular
carcinomas and nodules in the male and female mice in the mid-
dose 5 ppm and high-dose 10 ppm groups as compared to controls
(IARC, 1991).
In a study conducted by the National Cancer Institute (NCI) (NCI,
1977; NTP, 1977), 50 B6C3F1 mice of each sex, five weeks of
age, were fed technical-grade heptachlor (72% heptachlor, 18%
trans-chlordane, 2% cis-chlordane, 2% nonachlor, 1% chlordene,
0.2% hexachlorobutadiene) for 80 weeks, and then observed for
10 weeks.  Matched controls, 20 males and 10 females, were
combined with matched controls from other bioassays to generate
pooled controls consisting of 100 males and 80 females  (It should
be noted that the use of pooled controls is no longer acceptable in
animal bioassays).  Because of toxic effects, the initial dietary
concentrations of 10 and 20 mg/kg heptachlor were reduced
several times during the course of the study.  In males, time-
weighted average (TWA) concentrations of heptachlor in the diet
were 6 ppm (low-dose group) and 14 ppm (high-dose group),
whereas in females TWAs were 9 ppm (low-dose group) and 18
ppm (high-dose group).  Body weights of mice given either low
or high doses of heptachlor showed little or no difference
compared to those of control mice.  In females survival rates were
> 60% in the high-dose and ≥ 80% in the control and low-dose
groups.  In males, survival rates were high (≥ 70%) in all treated
and control groups.  The review panel of toxicologists from the
NAS concluded that there was a significant increase in the
combined incidence of hepatocarcinomas and nodules in the males
(p<0.042) and females (p<0.022) fed the highest dose of
heptachlor.  The nature of the “nodules” was not specified.  There
were no significant differences between treated animals and
controls in either sex when the statistical analysis was based only
on the incidence of hepatocellular carcinomas (IARC, 1991).
Liver tumors have also been reported in male and female mice
fed other structurally similar organochlorine pesticides, including
aldrin, dieldrin or chlordane (Reuber, 1978).  This suggests there
may be a common mechanism of liver tumor induction for these
structurally related cyclodiene compounds.
2. Rats:
In a 1955 study conducted by the Kettering Laboratory for Velsicol
Chemical Co., and reported by Epstein (1976), 20 CF rats of each
sex received 0, 1.5, 3.0, 5.0, 7.0, or 10.0 ppm of heptachlor in the
diet (purity unspecified) for 110 weeks, beginning at 10 weeks of
age.  Mortality rates in all test groups were high but were not
dose related.  Mortality ranged from 40 to 75% in the males, and
from 35 to 55% in female rats.  No weight loss was noted in
female groups, whereas in males small decreases in weight were
only seen in the 10 ppm group.  A review panel of pathologists
from the NAS concluded that heptachlor did not induce liver
tumors in rats in this study (IARC, 1991).  However, this study is
of limited value because of the inadequate number of animals per
dose group, especially in view of the high mortality rates (35 to
75%).  In addition, a full necropsy was not performed on the rats
that died during the experiment and there was no mention of the
number of animals examined histologically in each group.
In an 1972 Italian study by Cabral and colleagues (Cabral et al.,
1972 as cited in IARC, 1991), 10 mg heptachlor (97% purity) in
corn oil was given by gavage to 95 sucking Wistar rats of each
sex five times at two-day intervals; controls (19 males and 27
females) received corn oil alone.  The total number of tumors in
treated and control groups were comparable.  No information was
available on the tumor incidence by organ site, except that two
renal tumors were detected in female rats that received heptachlor
(dose level not specified).  The usefulness of this study for
determining the oncogenic potential of heptachlor is limited
because of the short duration of treatment, the small number of
controls, limited information on tumor incidence by organ site,
and the use of only one treatment dose which prevented an
evaluation of a dose-response effect.
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Another a heptachlor bioassay was conducted by NCI  on 50
Osborne-Mendel rats of each sex, starting at five weeks of age
(NTP, 1977).  The initial levels of technical heptachlor in the diet
were 80 and 160 ppm in the males, and 40 and 80 ppm in the
females, but because of toxic effects these doses were changed
several times during the course of the study.  Matched controls
consisted of 10 rats of each sex and pooled controls consisted of
60 rats of each sex.  In males TWAs dietary concentrations of
heptachlor were 38.9 and 77.9 ppm for the low- and high-doses,
respectively; in females, TWAs were 25.7 and 51.3 ppm for the
low- and high-dose groups, respectively. Average body weights
of male rats receiving the high but not the low dose of heptachlor
were consistently lower than those of untreated controls.  At 110
days 60 to 75% of all treated and control rats had survived.  In
contrast to mice (NCI, 1977; NTP, 1977), heptachlor did not induce
hepatic carcinomas in rats in this study.  There was a significant
increase in the number of thyroid follicular-cell neoplasms in
female (3/58 control; 14/38 high-dose, p<0.01) and male rats (4/
51 controls; 9/38 low-dose, p<0.05).  However, the incidence of
such thyroid follicular cell neoplasms in the male high-dose group
was only 3/38, indicating the absence of a dose-related effect.
The absence of a significant increase in thyroid tumors in the
high-dose group could reflect a reduction in food consumption.
The body weights in the high-dose group were consistently lower
than in the control group, indicating that the high-dose of
heptachlor was toxic to the rats.  The validity of this study is also
limited because the exposure time was only 80 weeks instead of
104 weeks currently used for a long-term rodent cancer bioassay
by the National Toxicology Program.  This study also used
inappropriate pooled controls.
3. Summary, Animal Studies (non-mammary sites):
In summary, the incidence of liver tumors was significantly
increased following dietary administration of heptachlor epoxide
in both male and female C3H mice (Epstein, 1976).  Dietary
administration of heptachlor also induced liver tumors in male
C3H mice (Epstein, 1976) and B6C3F1 mice in both sexes (NCI,
1977; NTP, 1977).  Diets containing a mixture of heptachlor and
heptachlor epoxide induced a significant increase in the combined
incidence of hepatocellular carcinomas and nodules in male and
female CD-1 mice (Epstein, 1976; IARC, 1991).  In contrast to
mice, dietary administration of heptachlor did not induce liver
tumors in CF (Epstein, 1976), Wistar (Cabral et al., 1972) or
Osborne-Mendel rats (NCI, 1977; NTP, 1977).  However, in the
NCI/NTP bioassay, heptachlor fed in the diet significantly
increased the incidence of thyroid follicular-cell neoplasms in both
male (p<0.05) and female (p<0.01) Osborne-Mendel rats.
C.  Current Classification of Carcinogenicity by Other
      Agencies:
1. IARC Classification:
The International Agency for Research on Cancer (IARC) has
determined that there is inadequate evidence in humans for the
carcinogenicity of heptachlor.  This agency has also assessed that
there is sufficient evidence in experimental animals for the
carcinogenicity of heptachlor, based on studies demonstrating
increased incidence of liver hepatocellular neoplasms in mice of
each sex, and thyroid follicular-cell neoplasms in rats of each
sex.  Overall, the IARC has determined that heptachlor is “possibly
carcinogenic to humans” and consequently assigned heptachlor
to Group 2B (IARC, 1991).
2. NTP Classification:  Not classified
3. EPA Classification:
The EPA has classified heptachlor in Group B2 as a “probable
human carcinogen” (IRIS, 1993; IRIS 1997).  Though the EPA
concluded that there is inadequate evidence of carcinogenicity
from human data, sufficient evidence exists for the carcinogenicity
of heptachlor and heptachlor epoxide in animals.  This is based
on the observation of benign and malignant tumors in both sexes
of multiple strains of mice treated with these chemicals.  Included
in their carcinogenicity assessment was a review of the long-term
carcinogenicity bioassays of heptachlor in male and female CH3
mice [unpublished FDA study reported in Epstein (1976), and in
male and female B6C3F1 mice (NCI, 1977; NTP, 1977)].  The
EPA has concluded that heptachlor caused an increase in the
incidence of liver carcinomas in mice (IRIS, 1997).  The EPA
also observed that in these studies, adequate numbers of animals
were observed for the majority of the expected lifetime and that
the incidence of liver carcinomas was increased in all data sets.
Supporting data of carinogenicity included that other structurally
related compounds have produced liver tumors in mice (IRIS,
1997). (IRIS, 1993; IRIS 1997).
V.  Critical Evaluation of Breast Carcinogenicity:
A. Human Studies:
1.  Adipose Tissue Levels:
Heptachlor is oxidized by microsomal enzymes to heptachlor
epoxide in animals and humans (Kutz et al., 1991a).  Because it
is lipophilic and has a very long half-life, heptachlor epoxide
concentrates in the food chain, and bioaccumulates and persists
in adipose tissues of humans (Frank et al., 1988; Kutz et al., 1991a;
Levine, 1991; Teufel et al., 1990; Wassermann et al., 1972).  In
the US population, adipose tissue levels of heptachlor epoxide
were found to be higher in those aged ≥ 45 years (0.098 ppm)
than in the 15 to 44 year (0.073 ppm) and 0 to 14 year (0.047
ppm) age groups (Levine, 1991).  Similar increases in the
concentration of heptachlor epoxide over the course of a lifetime
have been observed in other countries (Frank et al., 1988; Levine,
1991; Wassermann et al., 1972).
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Most of the reported values for heptachlor epoxide in the adipose
tissue of adults in North America has been reported to range
between 0.027 ppm (Hawaii) to 0.24 ppm (Monroe County, LA),
respectively, in samples obtained in the 1970s and 1980s
(Adeshina and Todd, 1990; Kutz et al., 1991b).  Results from the
National Human Adipose Tissue Survey summarized by Kutz et
al., (1991b) showed that the average levels of heptachlor epoxide
in the US population have been remarkably stable.  Average levels
of heptachlor epoxide were 0.09 ppm in 1970 (n=1412); 0.08 ppm
in 1976 (n=682) ; and 0.09 ppm in 1983 (n=407).  A more recent
study has reported similar average levels of heptachlor epoxide
(0.086 ppm) in 35 adipose samples obtained from autopsies
specimens of residents of North Texas in 1987-88 (Adeshina and
Todd, 1990).
A small study that examined organochlorine levels in postmortem
adipose tissue levels in 19 males and six females from El Paso,
Texas, reported mean levels of 0.12 ppm heptachlor, and 0.01
ppm heptachlor epoxide (Redetzke et al., 1993).  An interesting
finding was that the women in this study had significantly higher
levels of heptachlor at 0.31 ppm compared to the mean value of
0.06 ppm heptachlor in the men.  The authors suggest that the
higher level of heptachlor in the women may have indicated that
the women were exposed to a domestic source of heptachlor, such
heptachlor used in residential termite control.  However, air
samples were not taken from the homes or workplaces of the
subjects to confirm this hypothesis.
2.  Cow’s Milk and Human Breast Milk Levels:
Human milk contains 3 to 5% of lipids, and heptachlor has been
widely reported as a breast milk contaminant (Levine, 1991).
(Note on units:  studies report chemical concentrations in human
breast milk as either the level in whole milk, or the concentration
of the chemical per gram of milk fat).  A review of lactation studies
from Europe, Africa, Asia, and America reported that heptachlor
epoxide present in human milk fat ranged between 0.015 ppm
(Canada) to 0.72 ppm (Israel) (Jensen, 1991).  Analysis of human
milk fat samples obtained in the early 1980s from 1,436 women
residing in the US has revealed that heptachlor epoxide was present
above detection limits in 63.1% of the samples and averaged 91.4
ppb (Savage et al., 1981).  Savage et al. (1981) reported that in
the US the highest levels of heptachlor epoxide in human milk
fat were found in the Southeast (128 ppb, n=221), followed by
the Midwest (90.6 ppb, n=272), Southwest (75.8 ppb, n=178),
Northeast (71.8 ppb, n=144), and Northwest (66.1 ppb, n=91).
There are reports of agricultural misuse of heptachlor that resulted
in elevated levels of heptachlor epoxide in cow’s milk and human
breast milk in Hawaii (Allen et al., 1997; Rogan et al., 1991;
Smith, 1982).  The Hawaiian State Department of Health detected
unexpected high amounts of heptachlor epoxide in cow’s milk in
January of 1982 that were traced to “green chop” fed to dairy
cows over a 15 month period during 1981 and 1982.  The green
chop included heptachlor contaminated pineapple leaves (Rogan
et al., 1991; Smith, 1982).  Heptachlor was used on the pineapples
to prevent mealybug wilt, a condition caused by toxins released
into the pineapple by the parasitic mealybug.  Heptachlor was
used to kill ants that influenced the survival of the mealybug
population (Smith, 1982). It was found that 18 out of the 19 dairy
farms on Oahu used pineapple green chop for feeding dairy cattle.
All of the milk from the dairy farms was pooled for processing at
two facilities on Oahu.  Virtually all of the heptachlor contaminated
cow’s milk was sold on the island of Oahu, and with few
exceptions, was not exported to other Hawaiian islands or to the
mainland (Baker et al, 1991).  Levels of heptachlor in cow’s milk
were reported to be as high as 1.2 to 2.7 ppm (Smith, 1982; Baker
et al., 1991).  The FDA action level for heptachlor epoxide was
0.3 ppm in 1982 (Smith, 1982).
The heptachlor contamination in Hawaii appears to have
influenced levels of heptachlor epoxide in human breast milk.
The levels of heptachlor epoxide in 50 human breast milk samples
obtained from nursing women in Hawaii in 1977 were reported
to be relatively low, averaging 35 ppb in milk fat (0.035 ppm) in
women 18-24 years of age, and 27-44 ppb in women in women
30 to 37 years of age (Takahashi et al., 1981).  Levels in the early
1980s during the episode of the heptachlor contamination, were
reported to be threefold higher at 0.1 ppm [unpublished study
cited in (Rogan et al., 1991)], which was similar to the range of
heptachlor epoxide levels reported in human breast milk on the
US mainland during a similar time period (Savage et al., 1981).
Other researchers have reported that the levels of heptachlor
epoxide in 102 human milk samples obtained from Hawaiian
lactating women in the 1980s (0.036 + 0.013 ppm, lipid basis)
were comparable to levels of heptachlor epoxide found in US
mainland human milk samples (0.055 + 0.039 ppm) (Takei et al.,
1986).  In contrast, others (Allen et al., 1997) have cited
unpublished reports from the Heptachlor Research and Education
Foundation which reported heptachlor epoxide levels as high as
1.2 ppm in breast milk fat during 1981 to 1982 (Baker, 1994).
Ten years later in 1993, the levels of heptachlor epoxide in breast
milk and in the serum of adults and children on Oahu, was higher
than levels on neighboring islands and the US mainland
[unpublished study (Baker, 1994) as cited by (Allen et al., 1997)].
It has been suggested that studies be undertaken in Hawaii to
determine if exposure to heptachlor, and to many other
organochlorine pesticides that were used extensively on some of
the islands, may play a role the rising incidence rates of breast
cancer reported in Hawaii over the last several decades (Allen et
al., 1997).
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Another case of contamination of commercial cow’s milk occurred
in Van Buren, Arkansas in 1986.  Heptachlor metabolites,
components of technical chlordane, and chlordane metabolites
(heptachlor epoxide, trans-nonachlor and oxychlordane,
respectively) were found in the raw milk from 33 dairy farms
(Stehr-Green et al., 1986).  The source of the contamination was
discarded seed that had been treated with heptachlor and other
pesticides to make alcohol-based fuel, and the left over mash had
been sold as animal feed to the dairy farmers (Farley, 1988).
Heptachlor epoxide levels in raw milk were found to be as high
as 89.2 ppm.  Thousands of gallons of milk and dairy products
were subsequently removed from store shelves, and laboratory
analyses found the processed milk had heptachlor epoxide levels
as high as 12.6 ppm (fat basis) (Stehr-Green et al., 1986).
Subsequently, researchers attempted to evaluate the magnitude
of the exposure, and the presence of acute health effects in group
with the highest risk of exposure; the dairy farm families that had
consumed the raw, heptachlor contaminated milk (Stehr-Green
et al., 1986; Stehr-Green et al., 1988).  Serum samples were
collected from 45 individuals from 13 families for the
determination of heptachlor epoxide, oxychlordane, and trans-
nonalchor levels. Serum levels from heptachlor exposed families
were compared to serum samples from participants in the National
Health and Nutrition Examination Survey (NHANES) from
neighboring states who were known not be exposed to the
heptachlor contaminated milk.  Adjustments were made, using
covariance, for age and sex differences.  Exposed farm family
members had statistically significantly (p<0.01) higher mean
levels of serum heptachlor epoxide (0.81 + 0.94 ppb),
oxychlordane (0.7 + 0.75 ppb) and trans-nonachlor (0.79 + 0.60
ppb) compared with unexposed individuals from the NHANES
study (control values not provided). This study also assessed
whether liver function was affected in the dairy farm families
that had consumed heptachlor contaminated milk, compared to
85 individuals from dairy farm families who had not consumed
contaminated milk.  There were no differences in either levels of
liver function enzymes or the induction of liver microsomal
enzymes in the exposed and non-exposed dairy farm families
(Stehr-Green et al., 1986; Stehr-Green et al., 1988).  Data was
not available on long-term follow of this population in regard to
chronic disease states, including breast cancer.
A study has examined the relationship between occupational
exposure to heptachlor and levels of heptachlor epoxide in the
breast milk of Finnish women (Mussalo-Rauhamaa et al., 1988).
Over 50 to 60 metric tons of heptachlor was used in the
manufacture of plywood during the mid-1980s in Finland.  Scrap
wood was destroyed by burning, potentially releasing heptachlor
into the environment.  These investigators did not find that the
residues of heptachlor or heptachlor epoxide differed in 22
lactating women who worked in the plywood industry compared
to those who lived in plywood burning areas, or in “other” mothers.
Because of the widespread use of persistent organochlorine
pesticides in the US during the 1950s through the 1980s, and the
bioaccumulation in the breast adipose tissue of women and its
transfer to human milk, researchers have struggled with the
question of whether mothers should breast feed their infants.
Researchers at the National Institute of Environmental Health
Sciences (NIEHS) have conducted risk analyses comparing the
lives saved in the postneonatal period by breast feeding to the
estimated excess cancer deaths attributable to a variety of
organochlorine compounds in human breast milk.  These
researchers concluded that there is not sufficient evidence to advise
against breast feeding (Rogan et al., 1991).  This and a subsequent
study with commentary concluded that “in the vast majority of
women, the benefits of breast-feeding appear to outweigh the
risks...” (Rogan, 1996).
3. Case-Control Studies:
The ability of heptachlor epoxide to bioaccumulate in fat tissues
of the body has led some investigators to evaluate possible
associations between breast cancer and mammary fat levels of
heptachlor epoxide.  Only a few, very small case-control studies
have been conducted to determine if there is a possible association
between heptachlor/heptachlor epoxide residues in breast tissue
and the risk for breast cancer. Although these studies are not of
sufficient size to have the statistical power to accurately assess
whether there is or is not an association between body burdens of
heptachlor epoxide and cancer risk, we have presented these
studies because they are the only studies available on heptachlor
and breast cancer risk.  The results of these studies are presented
in Table 1, and are summarized below.
In a small pilot study, Falck et al. (1992) determined the levels of
organochlorine residues in the breast fat from 20 patients with
malignant breast tumors and 20 patients with benign breast
disease.  The levels of heptachlor epoxide plus oxychlordane in
patients with breast cancer were not statistically different from
those of control patients with benign breast disease.  This study
had several limitations.  Levels of heptachlor epoxide and
oxychlordane were not reported separately.  Cases and controls
were not matched for age, nor were other breast cancer risk factors
such as parity, reproductive history or menopausal status
controlled for in this study.  Tissue samples were obtained from
patients with benign breast disease; it would have been more
appropriate to obtain samples from non-cancer surgical controls
who were free of breast disease.
A study conducted by Mussalo-Rauhamaa et al. (1990) determined
the levels of heptachlor epoxide in breast fat samples from 44
breast cancer patients compared with postmortem samples
obtained from 33 cancer-free Finnish women of similar weight,
height and age.  Background information on age weight, height,
occupation, residence, fish consumption, parity and lactation
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history was obtained by questionnaire from the breast cancer
patients; similar background information was obtained from
relatives of most of the deceased controls.  More women with
breast cancer were nulliparous (14/44) compared to the women
without breast cancer (4/33), but these differences were not
statistically different (p=0.16).  While the levels of heptachlor
epoxide were higher in the women with breast cancer compared
to the women without breast cancer, there was high variability
within the values for each group, and the mean levels of heptachlor
epoxide were not statistically different between cases and controls
(Mussalo-Rauhamaa et al., 1990).  This study is of limited value
because of the very small sample size, use of postmortem controls,
and because background information on controls could only be
obtained by proxy.
In a third epidemiological study, there were higher levels of
heptachlor epoxide in breast adipose tissues from nine patients
with mammary carcinomas compared to five controls (Wasserman
et al., 1976).  It should be noted that this was an extremely poor
quality study, both in terms of the design of the study and the
statistical analysis of the results.  The sample size was extremely
small, and there was no attempt to collect background information
on the cases and controls.  There was no attempt made to control
for confounding breast cancer risk factors such as reproductive
history, age, weight, height or parity.  The statistical analysis of
the data was minimal; only means and ranges were available,
standard deviations were not computed, and no statistical
comparisons were made between the levels of organochlorine
residues in the adipose tissues of breast cancer patients as
compared to controls.  This study is only cited here for the sake
of completeness and to point out its severe limitations.
These studies do not provide sufficient evidence of a causal
relationship between heptachlor exposure and breast
carcinogenicity.  None of the three studies found a statistically
significantly higher level of heptachlor epoxide in breast cancer
patients compared to controls without the disease.  These studies
also have experimental design limitations.  None of the studies
attempted to characterize the exposure to heptachlor or chlordane
(i.e., diet, occupational, residential termiticide treatment).  All
Table 1.  Breast adipose tissue concentrations (ppm) of heptachlor epoxide residues in women with
breast cancer (cases) or women without breast cancer (controls)
—————————————————————————————————————————
Authors Cases Controls p value
Falck et al., 0.136 + 0.053 ab (20) 0.121 + 0.053ac (20) 0.36 (NS)
1992
Mussalo- 0.03 ± 0.02 a (12) 0.02 ± 0.02ad (12) 0.62 (NS)
Rauhamaa
et al., 1990




 Mean + SD
b
 heptachlor epoxide + oxychlordane
c
 controls had benign breast disease
d
  samples obtained from deceased patients free of breast cancer
Parentheses: number of subjects
NS = not significant at p<0.05
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three studies were based on a very small number of individuals,
less than 25 per group, which limits the power of the statistical
tests.  In one study, control subjects were not free of breast disease
(Falck, et al. 1992).  Two of the studies used autopsy specimens
to obtain control tissue, and limited information could be obtained
by proxy on the background characteristics and confounding breast
cancer risk factors from deceased cases and controls (Mussalo-
Rauhamaa, et al. 1990;  Wassermann, et al. 1976).  None of the
studies carefully controlled for confounding breast cancer risk
factors.  Larger population-based case-control studies will be
required to determine whether higher body burdens of heptachlor
metabolites do or do not affect the risk of developing breast cancer.
B. Animal Studies:
To the best of our knowledge, there have been no reports of
increased incidence of mammary tumors in oncogenicity studies
of heptachlor or heptachlor epoxide-treated laboratory animals.
C. Other Relevant Data on Breast Cancer Risk:
1. Immunological Effects:
A compromised immune system may affect host defenses against
cancer. There is some evidence from studies in mice that in utero
exposures to chlordane can adversely affect the developing
immune system of the fetus [see BCERF Critical Evaluation on
chlordane] (Blaylock and Mehendale, 1995; Blyler et al., 1994;
Lau et al., 1990; Menna et al., 1985; Spyker-Cranmer et al., 1982).
No in vivo  animal studies were found that evaluated the possible
immunotoxic effects of heptachlor in utero or in adult animals.
However, one of the predominant isomers of chlordane, trans-
chlordane can be metabolized to heptachlor (IARC, 1991).
Heptachlor has been shown to induce differentiation of human
myeloblastic leukemia cells (Chuang et al., 1993; Chuang et al.,
1991), proliferation of rhesus monkey lymphocytes (Chuang et
al., 1992) and stimulation of superoxide generation by pig
leukocytes (Suzaki et al., 1988).  However, all the above studies
on heptachlor have looked at the response of immune-competent
cells in culture, and such assays have been shown by other
researchers to be of limited value in predicting the in vivo effect
of pesticides on the immune system (Johnson et al., 1987).  Hence,
in vivo animal studies are needed to determine if exposures to
heptachlor can alter host immune response and susceptibility to
cancer.
Whether heptachlor exposure affects immune response in humans
and subsequent susceptibility of humans to breast cancer is not
known.  We were not able to locate studies in the scientific
literature that have evaluated heptachlor exposure and immune
response in humans.  One small study reported some level of
increased titer of autoimmune antibodies in 11 out of 12
individuals exposed to technical chlordane in the home or in a
work environment (McConnachie and Zahalsky, 1992).  Since
technical chlordane is approximately 20% heptachlor, further
studies are needed to determine if heptachlor or heptachlor epoxide
affects immune function and subsequent cancer risk in humans.
2. Mutagenicity:
Heptachlor is not mutagenic in bacteria (Probst et al., 1981) or
mammalian liver cells (Telang et al., 1982).  Heptachlor was also
shown to be non-genotoxic in rodent hepatocytes (Maslansky,
1981; Probst et al., 1981) and a SOS microplate assay (Venkat et
al., 1995).  Dominant lethal assays were also negative for
heptachlor and its epoxide (Arnold et al., 1977).  These studies
support the conclusion that heptachlor and heptachlor epoxide
are not genotoxic.
3. Evidence of Tumor Promotion:
B6C3F1 male mice were pretreated with the carcinogen
diethylnitrosamine (DEN) (20 ppm in the drinking water) for 14
weeks, and after a 4-week period were fed 5 or 10 ppm technical
grade heptachlor in the diet for 25 weeks.  Approximately 80% of
the heptachlor-treated mice developed liver tumors, compared to
40% in mice that received a control diet without heptachlor after
DEN-pretreatment (Williams and Numoto, 1984).  A similar
incidence of liver tumors was reported in mice pretreated with 25
or 50 ppm technical chlordane.  These results suggest that both
technical heptachlor and chlordane are promoters of liver tumors
in male B6C3F1 mice.
4. Signal Transduction and Intercellular Communication:
Gap junctional intercellular communication (GJIC) plays an
important role in the regulation of cell proliferation and
differentiation, and agents that affect GJIC may affect cancer risk.
Many non-genotoxic chemical carcinogens and tumor promoters
inhibit GJIC in vitro and in vivo  (Ruch et al., 1990).  Heptachlor
has been shown to inhibit GJIC in mouse and rat hepatocytes
(Matesic et al., 1994; Ruch et al., 1990).  Heptachlor is capable
of promoting hepatocarcinomas in mice (Williams and Numoto,
1984).  The inhibition of GJIC may represent one possible
mechanism by which heptachlor and heptachlor epoxide promote
the formation of tumors in the mouse liver.  Heptachlor and
heptachlor epoxide also inhibit GJIC in normal human breast
epithelial cells at non-cytotoxic concentrations (Nomata et al.,
1996).  Therefore, animals studies are needed to determine if these
insecticides could act as mammary tumor promoters in the
presence of known mammary carcinogens such as
dimethylbenz[a]anthracene (DMBA) or N-nitroso-N-methylurea
(NMU).
5. Disruption of the Endocrine System:
A number of studies have described the ability of technical
heptachlor and its metabolites to disrupt endocrine pathways.
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Disturbance of the endocrine system may occur through changes
in the activity of liver microsomal enzymes which are important
in the metabolism and degradation of ovarian steroids.  Endocrine
disruption may also occur at the level of the target tissues.  The
significance of these studies are discussed below.
a. Effects on Hepatic Microsomal Hydroxylases:
Studies have investigated the ability of heptachlor to affect the
metabolism of steroids in the livers of laboratory animals.  In a
study reported by Haake et al. (1987) three week old male Long
Evans rats received an intraperitoneal injection of 250 mmol/kg
heptachlor (purity unspecified) in corn oil and were sacrificed
five days later.  Heptachlor induced an increase in the activity of
several liver microsomal monoxygenases, including the P-450
isoenzymes involved in the 16α− and 16β-hydroxylation of
testosterone and induced benzo[a]pyrene hydroxylase.
In another study, Welch et al. (1971) showed that intraperitoneal
(i.p.) treatment of immature female rats with 10 mg/kg/day
heptachlor for seven days induced a 2.5-fold increase in the
metabolism of estrone by liver microsomal enzymes resulting in
increases in the secretion of estrone ‘polar metabolites.’  The exact
nature of the polar estrone metabolites was not specified.
Both of these studies suggest that heptachlor may affect
hydroxylation pathways of steroids, including estrogen (Haake
et al., 1987; Welch et al., 1971).  There has been increased interest
in the role polar metabolites of estrogen may play in breast cancer
risk.  Several researchers have hypothesized, and have offered
preliminary evidence, that the stimulation of P-450 microsomal
hydroxylation pathways by some organochlorine pesticides yields
estrogen metabolites that may increase breast cancer risk, while
other hydroxylation pathways yields metabolites that may decrease
breast cancer risk (Bradlow et al., 1995; Davis et al., 1997).  The
polar estrone metabolite associated with an increased breast cancer
risk is called 16-alpha hydroxyestrone (16-OHE1), and the
metabolite associated with possible decreased breast cancer risk
is called 2-hydroxyestrone (2-OHE1).  Some studies have
suggested that 16-OHE1 can enhance breast cell growth, increase
unscheduled DNA synthesis, and increase anchorage independent
growth.  In contrast, while the 2-OHE1 does not have any of these
properties, it is a very weak estrogen, and may even be protective
against breast cancer (Davis et al., 1997; Suto et al., 1993; Telang
et al., 1992a; Telang et al., 1992b; Tiwari et al., 1994).
Studies with the MCF-7 breast tumor cell line have shown that
some pesticides, including DDT and atrazine, decreased the
amount of 2-OHE1 formed by these cells while increasing the
levels of 16-OHE1 formed (Bradlow et al., 1995).  Studies have
not yet tested the effect of heptachlor or heptachlor epoxide
administration on the formation of these hydroxylation products
in vivo or in vitro.  Therefore, further studies are needed to
determine if P-450 dependent estrogen hydroxylation pathways
are induced by heptachlor and heptachlor epoxide, and if the
metabolites generated are potentially genotoxic or non-genotoxic
to breast cells.
b. Evidence of Estrogenicity:
Increased exposure to estrogen has been associated with increased
breast cancer risk (Dorgan et al., 1997; Harris et al., 1992; Pike et
al., 1993).  Whether or not heptachlor can mimic estrogen effects
would help define its potential to affect breast cancer risk.  Soto
et al. (1995) have developed an E-SCREEN assay designed to
test the “estrogenicity” of xenobiotics based on their ability to
stimulate the proliferation of estrogen-dependent human breast
MCF-7 cells relative to estradiol-17β (100% potency induced by
10-100 pM estradiol-17β).  These authors state that the MCF-7
proliferation test is biologically equivalent to the classic test of
estrogen-induced increase in mitotic activity in immature rodent
uteri.  Heptachlor did not induce MCF-7 proliferation in the E-
SCREEN assay (Soto et al., 1995).  These results suggest that
heptachlor is not estrogenic and should be confirmed by other in
vivo and in vitro screening tests for estrogenicity.
c. Effects on Reproduction:
Studies have found that technical heptachlor is a reproductive
toxin in rats (Rani and Krishnakumari, 1995).  Technical
heptachlor was fed to 30 CFT-Wistar rats of each sex at 0, 45.25,
and 90.5 mg/kg for males, and 0, 25 and 50 mg/kg for females.
Females and males were treated for 14 and 70 days prior to mating,
respectively.  The low dose of 25 mg/kg heptachlor significantly
decreased serum levels of both estradiol and progesterone in
females (p<0.05).  In contrast, diets containing the high
50 mg/kg dose of heptachlor had no effect on the rats’ secretion
of estrogen and progesterone.  Both doses of heptachlor
significantly reduced the percentage of pregnancies (p<0.01).  In
males, heptachlor induced a dose-dependent decrease in sperm
count (18.5 and 67.2%, respectively). This study demonstrates
that heptachlor can disrupt the secretion of steroid hormones and
interfere with fertility in both sexes.
No studies have been conducted to test the effects of heptachlor
on the female rodent estrous cycle or effects on circulating levels
of estrogen or progesterone.
A lack of reproductive success has been reported in female mink
fed technical grade heptachlor at 6.25, 12.5, and 25 ppm (mg/kg)
prior to and throughout the reproductive period (181 days) (Crum
et al., 1993).  However, the mortality rates of the female dams
(67% of the 12.5 ppm group and 100% in the 25 ppm group)
were so high that dose-response relationships could not be
effectively evaluated.  Significant weight loss was also reported
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in the 12.5 and 25 ppm females during the first 12 weeks of the
study.  Consumption of the 6.25 ppm heptachlor diet by the female
mink prior to breeding and before gestation had no effect on pup
birth weight or pup survival.  This study did, however, provide
evidence of placental transfer of heptachlor/heptachlor epoxide
to the pups, as evidenced by increased body burdens of heptachlor
epoxide at birth in pups born to dams fed 6.25 ppm (mean 0.86
µg heptachlor epoxide/g birth wt) or 12.5 ppm heptachlor (mean
3.08 µg/g birth wt) compared to controls (Crum et al., 1993).
In summary, these studies indicate that heptachlor disrupts the
endocrine system by increasing the activity of liver microsomal
enzymes which are involved in the metabolism of testosterone
and estrogens (Haake et al., 1987; Welch et al., 1971).  Further
studies are needed to determine if heptachlor can affect the P-450
mediated hydroxylation pathways of estrone, and affect levels of
estrone metabolites associated with genotoxic effects in breast
cells.  Heptachlor is a reproductive toxin in rats (Rani and
Krishnakumari, 1995).  Mink pups born to dams fed heptachlor
retain heptachlor epoxide in their tissues (Crum et al., 1993).
Heptachlor does not appear to be estrogenic as determined by the
E-SCREEN assay (Soto et al., 1995).
VI.  Other Relevant Information
A. Environmental Fate and Potential for Human Exposure
Heptachlor is readily oxidized to heptachlor epoxide in the
environment (ATSDR, 1993; IARC, 1987).  In animals and
humans, the principal metabolites of heptachlor are heptachlor
epoxide and 1-exo-hydroxychlordene epoxide.  Heptachlor
epoxide does accumulate in body tissues and is excreted in the
feces and urine.  The 1-exo-hydroxychlordene epoxide is excreted
in the urine (Tomlin, 1994).  The half-life of heptachlor epoxide
is longer than heptachlor, and hence, heptachlor epoxide is an
extremely persistent metabolite and can bioaccumulate in fat tissue
(See Section VII. A on Human Tissues Levels of Heptachlor and
Heptachlor Epoxide).  Because heptachlor and heptachlor epoxide
are very lipophilic and not very water soluble, drinking water
does not constitute a major route of exposure (ATSDR, 1993).
The 90th percentile levels of heptachlor epoxide in the
groundwater of New Jersey in the early 1980s has been reported
to be 0.1 ppb, which is half of the MCL for drinking water at
0.0002 mg/L (equal to 0.2 ppb) (Page, 1981).  Heptachlor epoxide
was rarely found in water samples taken from the Grand, Saugeen,
and Thames Rivers in Ontario, Canada (Frank et al., 1991).  In
samples of 466 water samples taken from these rivers from
1986-90, only a single sample in the Grand and Saugeen River
and none in the Thames River had detectable levels of heptachlor
epoxide.
Both heptachlor and heptachlor epoxide adsorb strongly to soils
and lake/river bed sediments.  The half-life of heptachlor in soil
has been reported to range between 0.75 and 2 years (IARC, 1991).
Heptachlor and heptachlor epoxide have the potential of
bioconcentrating in the food chain in aquatic and terrestrial
animals.  This is why one of the major routes of exposure is
through the diet, primarily in milk and dairy products, root
vegetables, meat, fish, and poultry (ATSDR, 1993).
The contamination of cow’s milk in Hawaiian dairy cows fed
“green chop”, leaves from pineapples treated with heptachlor,
during the early 1980s has been previously discussed in this
Critical Evaluation (Smith, 1982).  BCERF could not locate reports
documenting adverse health effects in the individuals who drank
the heptachlor-contaminated cow’s milk, or in the offspring of
women exposed during their pregnancy, or in infants fed breast
milk with elevated levels of heptachlor/heptachlor epoxide (Stehr-
Green et al., 1986; Le Marchand et al., 1986).  Researchers have
recommended a surveillance program to assess the incidence of
adverse health effects, including the incidence of breast cancer
(Allen et al., 1997).
The National Contaminant Biomonitoring Program has surveyed
the presence of organochlorine chemicals in freshwater fish in
the US (including Hawaii), and reported on trends in the levels of
heptachlor and heptachlor epoxide levels in fish from 1976 to
1984.  Since heptachlor is converted to heptachlor epoxide by
many organisms, including fish, relatively little unmetabolized
heptachlor was detected in fish.  The concentrations of heptachlor
epoxide in fresh water fish in 1984 were highest in Hawaii (mean
0.20 µg/g wet wt), followed by the Midwest, especially in fish
from Lake Michigan (0.015 to 0.3 µg/g wet wt), and in the rivers
of Mississippi, Missouri, Ohio, and Illinois (0.01 µg/g wet wt)
(Schmitt et al., 1990).  A 1985 study of contaminants in fish from
Midwestern rivers reported levels of heptachlor epoxide as high
as 0.48 mg/kg in fish obtained from the Sheboygan River in
Wisconsin, compared to levels of 0.02 mg/kg in fish from the
Milwaukee River (De Vault, 1985).
There are relatively few recent reports on the levels of heptachlor
epoxide in the diet of Americans.  One study (MacIntosh et al.,
1996) has assessed dietary exposure to heptachlor epoxide by
matching food consumption patterns as collected from two large
epidemiological studies, the Nurse’s Health Study, and the Health
Professional’s Follow-up Study, with the pesticide residue levels
reported for 236 foods in the Food and Drug Administration (FDA)
1986-1991 Total Diet Study.  The strength of this study is that it
estimated dietary exposure to pesticide residues in a large cohort;
78,882 females and 38,075 males.  They estimated the mean
dietary exposure to heptachlor epoxide to be 0.3 µg per day, with
a maximum concentration of 1.0 µg (MacIntosh et al., 1996).  The
World Health Organization’s (WHO) Acceptable Daily Intake
(ADI) for heptachlor and heptachlor epoxide (combined) is 0.0001
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mg/kg (WHO, 1993); which for a 60 kg female would be 6 µg.
Therefore the estimated levels of heptachlor epoxide in the diets
of most adult Americans appear to be below the ADI.
Besides diet, another primary route of exposure is through
inhalation.  Both heptachlor and heptachlor epoxide have low
vapor pressures and can volatilize from soil particles into the air.
Kamble et al. (1992) reported that in homes treated with technical
chlordane (heptachlor makes up to 20% of technical chlordane),
air levels of heptachlor were consistently higher than levels of
chlordane, and these levels were similar to or higher than quantities
allowed by National Research Council (NRC) guidelines
(2 µg/ m3) (Kamble et al., 1992).  In this study, air was sampled
for four hours from the basement, kitchen and one bedroom of
each home (n=19), but only mean values per residence were
reported.  Levels of heptachlor were highest during treatment
(5 µg/m3), and were between 3 and 2 µg / m3 in the air 180 days
posttreatment.
Since a higher proportion of homes in the Southeastern US were
treated in the past for termites with chlordane and heptachlor
compared to other areas in the US, these southern homes have
the greatest potential for having detectable levels of heptachlor
in indoor air (ATSDR, 1993).  Those persons who live in
heptachlor or chlordane treated homes and spend most of their
time indoors (i.e., limited mobility, retired persons, infants, young
children) may have the potential for exposure to heptachlor or
heptachlor epoxide via indoor air (ATSDR, 1993).
Pilot studies have been conducted to develop methods for sampling
the indoor air and household dust for pesticides residues.  This
includes the development of the HVS3 dust sampler to determine
dislodgable pesticide residues in carpets (Lewis et al. 1994).  This
study also estimated childhood hand-to-mouth exposures to
pesticides using bare-hand prints, and solvent hand rinses.  Nine
homes were included in this pilot study.  Mean heptachlor levels
were:  0.62 µg /m3 in dislogable carpet dust; 0.02 µg/m3 by hand
press; 0.04 µg in child hand rinses, 0.07µg /m3 in the household
air, and 0.01 mg /g in play area soil.  Therefore, carpet dust had
more heptachlor than outdoor play soil.  No indication was given
as to where the soil sample was obtained.  While more studies are
needed to improve methods to predict how household dust may
contribute to the ingestion of heptachlor, these preliminary results
do indicate that residues are present in the household dusts of
some homes, and may contribute to heptachlor exposure.
Because heptachlor and heptachlor epoxide can be in soils around
foundations treated with chlordane or heptachlor, inhalation can
take place when digging or handling the contaminated soil.
Therefore, activities such as gardening close (2-3 feet) to
foundations of homes or buildings treated with chlordane or
heptachlor should be discouraged.  Individuals living near
hazardous waste sites contaminated with heptachlor or chlordane
could also be exposed to heptachlor or heptachlor epoxide in air
or soil (ATSDR, 1993).
An EPA sponsored study (Whitmore et al., 1994) has attempted
to determine the nonoccupational exposure to heptachlor via
inhalation and dietary routes. The study was conducted in an area
of relatively low pesticide use, Springfield/Chicopee, MA and
high domestic use of pesticides, Jacksonville, FL.  To estimate
seasonal variations in exposure, samples were taken in the summer
of 1986, the spring of 1987, and the winter of 1988.  Samples of
49 to 72 persons participated per site, per season.  Inhalation
exposure was measured by analyzing 24-hour indoor, personal
and outdoor air samples.  Dietary exposure to pesticides also was
estimated through the use of a 24-hour dietary recall questionnaire
and the values from the USDA Total Diet Survey’s levels of
pesticide residues on raw agricultural commodities, and by
analyzing tap water samples.  Indoor and personal air levels of
heptachlor tended to be higher indoors than outdoor, and higher
in Jacksonville than in Springfield/Chicopee. Heptachlor levels
in the air tended to be highest in summer, lower in spring, and
lowest in winter.  The highest levels reported were in the summer
in Jacksonville with a mean indoor air concentration of
163 ng/m3.  Mean air concentrations for heptachlor were 2,312
ng/day in Jacksonville and 544 ng/day for Springfield.  These
levels were higher than estimated dietary exposures, with 155 ng
heptachlor/day in Jacksonville and a comparable 150 ng
heptachlor/day in Springfield.  This study would suggest that
inhalation is the major route of exposure to heptachlor.  However,
it should be noted that dust samples were only obtained in nine
homes and because of methodological problems, values were not
reported, so it is not known to what extent household dust would
have contributed to nonoccupational heptachlor exposure in this
study.
Those who have been occupationally exposed to heptachlor or
that applied heptachlor in their homes may have been exposed to
heptachlor by inhalation and/or by dermal contact if protective
clothing were not worn.  Occupations with potential for exposure
to heptachlor include:  1) agricultural workers who used, mixed,
or applied heptachlor or chlordane (technical chlordane contains
heptachlor), 2) pesticide applicators, 3) lawn care workers, 4) those
employed in manufacturing operations, such as plywood
manufacturing, or those who were or are currently employed at
heptachlor or chlordane manufacturing plants.  Another potentially
exposed population would include those who handled or laundered
work clothing contaminated with heptachlor.  Virtually all of the
studies that have followed occupational exposures to heptachlor
and the incidence of cancer deaths has been done on male workers
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employed in a heptachlor manufacturing plant or male pesticide
applicators (see section IV. of this Critical Evaluation).  No
occupational studies were located on women exposed to
heptachlor and cancer risk.
VII.  Summary and Recommendation for Breast
         Cancer Risk Classification:
A. Breast Cancer Risk Classification:
There is inadequate evidence to classify heptachlor as a “human
breast carcinogen” (see Appendix B for BCERF Breast Cancer
Risk Classification scheme). Because of the insufficient evidence
of human breast carcinogenicity, no evidence of mammary
carcinogenicity in experimental animals, and limited evidence of
mechanisms by which heptachlor and heptachlor epoxide may
affect breast cancer risk, we conclude that these chemicals should
be classified in Group 3, “inadequate evidence for classification
of breast cancer risk.”  These conclusions are based on the
following evidence:
•  The available human studies provide insufficient evidence
to conclude that heptachlor or heptachlor epoxide exposure
causes breast cancer in women.  Case-control studies on the
breast carcinogenicity of heptachlor in humans are inadequate
because:  1. they were based on very few cases (less than 25 per
group) limiting their statistical power; 2.  studies did not provide
or characterize exposure to heptachlor or heptachlor epoxide;
3. some of these studies used inappropriate controls, including
women with a history of benign breast disease; and 4. none of the
studies adequately controlled for confounding breast cancer risk
factors (Falck et al., 1992; Mussalo-Rauhamaa et al., 1990;
Wassermann et al., 1976).
•  There is no evidence that heptachlor or heptachlor
epoxide is a mammary carcinogen in long-term animal
cancer bioassays.
•  There is limited evidence of various mechanisms by which
heptachlor may affect breast cancer risk.  These data include:
heptachlor’s persistency in the environment; the potential for
continued exposure to human populations (ATSDR, 1993); the
ability to affect the metabolism of estrone by increasing the activity
of hepatic microsomal steroid hydroxylases (Haake et al., 1987;
Welch et al., 1971); the ability of heptachlor to promote liver
tumors (Williams and Numoto, 1984); the ability to affect the
differentiation (Chuang et al., 1993; Chuang et al., 1991) and
mitogenic response (Chuang et al., 1992) in immune competent
cells ; and the ability to interrupt gap junctional communications
between cells (Haake et al., 1987; Welch et al., 1971).  However,
further research will need to be conducted to determine if
heptachlor or heptachlor epoxide affects breast cancer risk by any
of these mechanisms.
VIII.  Research Gaps and Other
           Recommendations:
•  Large-scale, case-control studies are needed to determine if
women with breast cancer have higher levels of heptachlor or
heptachlor metabolites in their blood and/or breast fat than women
without the disease.
•  Animal studies are needed to evaluate heptachlor and heptachlor
epoxide’s potential to be a co-carcinogen and / or a tumor promoter
of known mammary gland carcinogens such as 7,
12-dimethylbenz[a]anthracene (DMBA) and N- nitroso-N -
methylurea (NMU).
•  Populations of women with known exposures to heptachlor/
heptachlor epoxide should be identified and monitored to
determine if past exposures influence health-related effects,
including the incidence of breast cancer.  This includes: 1) women
exposed to technical heptachlor or technical chlordane in
manufacturing facilities; 2) female agricultural workers who
worked in fields treated with chlordane or heptachlor; 3) female
spouses of men exposed to chlordane occupationally (agricultural
workers, pesticide applicators, lawn care workers) who may have
been exposed by handling or laundering contaminated clothing;
and 4) Hawaiian and Arkansas women and offspring of the women
exposed to heptachlor/heptachlor epoxide contaminated cow’s
milk or breast milk.
•  Studies are needed to determine the effect of heptachlor/
heptachlor epoxide exposure on estrogen metabolism in animal
models.  This includes the short- and long-term effects of
heptachlor on: circulating blood levels of estradiol-17β,  effects
on binding of ligands to the estrogen receptor; and if P-450
dependent hydroxylation pathways are induced by heptachlor/
heptachlor epoxide, and whether the hydroxylated estrone
metabolites generated are potentially genotoxic to breast cells.
•  Further studies are needed to determine if heptachlor/heptachlor
epoxide can compromise the immune system in ways that will
affect the body’s defense mechanisms against breast cancer.
Studies should be conducted to determine if animals exposed to
heptachlor/heptachlor epoxide in utero, or as adults, and
subsequently exposed to transplantable mammary tumors cells,
develop higher incidences of mammary tumors.  Studies following
human populations exposed to heptachlor should include an
assessment of immune function, as well as breast cancer incidence,
to determine if heptachlor or heptachlor epoxide may affect breast
cancer risk by compromising immune function.
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IX.  Summary of Human Studies Currently Being
       Conducted:
We have recommended the need for more epidemiological studies
on breast cancer incidence rates in women with exposure to
heptachlor /heptachlor epoxide.  There are several studies that
are currently being conducted to address this research need.  The
summaries of these studies provided below are adapted from
abstracts in the 1997 and 1998 Computer Retrieval of Information
on Scientific Projects Database (CRISP).  CRISP is a searchable
database of federally funded biomedical research projects
conducted at universities, hospitals, and other research institutions
that can be accessed via the web <http://eos12.dcrt.nih.gov:8002/
crisp_pilot/owa/crisp.main> or by Gopher Menu <gopher://
gopher.nih.gov:70/11/res/crisp>.
Breast Cancer and the Environment on Long Island
(PI: M.D. Gammon, Columbia University School of Public
Health, New York, NY)
The goal of this collaborative project among New York City and
Long Island researchers is to determine whether environmental
contaminants, including organochlorine pesticides, increase the
risk of breast cancer among women on Long Island, New York.
This investigation is a five-year, population-based case-control
study.  All new cases of breast cancer diagnosed during a
12-month period in residents from Nassau and Suffolk County,
Long Island, NY will be included in this study.  Population based
controls will be matched to cases by 5-year age groups.  Completed
in-home interviews are expected for 80% of eligible subjects
(1,623 cases and 1,623 controls).  About 60% of all respondents
are expected to provide biologic specimens (urine and blood).
Laboratory analyses include determination of organochlorine
compounds and pesticides in the blood, and urinary markers of
estrogen metabolism.  Home samples of water, soil, and dust will
be collected among women who have resided in their homes for
15 years or longer, and will be analyzed for organochlorine
pesticides.  For all respondents, historic environmental exposure
to these compounds will also be calculated using geographic
modeling techniques, as well as self-reports of occupational and
residential exposure.
Organochlorine Residue Levels and Risk of Breast Cancer
(PI:  L. Bernstein, University of Southern California School
of Medicine, Los Angeles, CA)
This project is a case-control study to determine if there is an
association between the levels of organochlorine residues in serum
and increased risk of breast cancer among African-American
women.  The study will be added on to ongoing study funded by
the National Institute of Child Health and Development.  Blood
will be obtained from 300 African-American breast cancer cases
and 300 controls in the Los Angeles area.  These blood samples
will be analyzed for serum organochlorine pesticide residues,
including  heptachlor epoxide, oxychlordane, trans-nonachlor.
Serum residue levels will be examined in relation to odds of breast
cancer in multivariate unconditional logistic regression models.
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XI.  Appendix A.  Common Abbreviations, Acronyms and Symbols:
ADI Allowable Daily Intake, set by the World Health
Organization
ATSDR Agency for Toxic Substances Disease Registry
BCERF Cornell Program on Breast Cancer and 
Environmental Risk Factors in New York State
bwt body weight
C carbon
CAS Chemical Abstract Service
CASRN Chemical Abstract Service Registry Number
CfE Cornell University Center for the Environment
CI Confidence Interval
Cl chlorine
CRISP Computer Retrieval of Information on Scientific
Projects; database of scientific intra- and 
extramural projects supported by the Dept. of
Health and Human Services (i.e., NIH, EPA,
USDA)
DEC Department of Environmental Conservation
DEN diethylnitrosamine; a liver carcinogen
DMBA 7,12-dimethylbenz[a]anthracene; known 
mammary carcinogen
DNA deoxyribonucleic acid
EPA United States Environmental Protection Agency
ER estrogen receptor
E-SCREEN screening assay for estrogenicity that measures
proliferative response in  estrogen-dependent
breast tumor cells
FDA Food and Drug Administration
CIJC gap junctional intercellular communication
GM-CFU granulocyte-macrophage colony-forming unit
HA The health advisories are nonenforceable limits
of the concentration of the chemical in the
drinking water that is not expected to cause any
adverse noncarcinogenic health effects when
consumed for no more than the time period
specified, with a margin of safety
IARC International Agency for Research on Cancer,
headquartered in Lyon, France
ICET Cornell Institute for Comparative and 
Environmental Toxicology
i.p. Interperitoneal
IRDC International Research and Development 
Corporation
IRIS Integrated Risk Information System; Database
maintained by the EPA available through the




LI Long Island, New York
µg microgram
mg milligram
MCF-7 Michigan Cancer Foundation; cells derived
from human breast tumor
MCL Maximum Contaminant Level; enforceable
limit set by the EPA which sets the maximum




n number of subjects/animals in the group
ng nanogram
NA Not available
NAS National Academy of Science
NHANES National Health and Examination Survey
NHATS National Human Adipose Tissue Survey
NHL non-Hodgkin’s lymphoma
NIOSH National Institute of Occupational Safety and
Health
NCI National Cancer Institute
NIEHS National Institute of Environmental Health and
Safety
NIH National Institutes of Health
NMU N-nitroso-N-methyurea; mammary carcinogen
NOEL No observed effect level
NRC National Research Council
NS Not statistically significant
NTIS National Technical Information Service; 
repository for federal agency technical reports
NTP National Toxicology Program
NY New York
NYS New York State
OR Odds Ratio
OSHA Occupational Safety and Health Administration
pM picomole(s)
ppm parts per million
ppb parts per billion




SHE Syrian hamster embryo
SMR Standardized Mortality Ratio; SMR= the ratio
of “observed” to “expected” deaths
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TMA Time-weighted average
US United States
USC University of Southern California
USDA United States Department of Agriculture










≥ greater than or equal to
% percent
p p value
± plus or minus
= equal
® registered trademark
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XII.  Appendix B. BCERF Critical Evaluations of Breast Cancer Risk
This includes an overview of the Critical Evaluations and explanation of the BCERF Breast Cancer Risk Classification Scheme
The Process:
Starting Point - Existing Critical Evaluations on Evidence of Carcinogenicity
IARC  Monographs (International Agency for Research on Cancer)
NTP ARC (National Toxicology Program, Annual Report on Carcinogens)
ATDSR (Agency for Toxic Disease Substance Registry of the CDC)
Conduct Literature Searches using databases to obtain historical and the most recent information; i.e. Toxline, Medline, Biosis,
Cancerlit
-Peer-reviewed scientific literature-available through Cornell libraries and interlibrary loans.
-Technical Reports-NTIS-National Technical Information Service
-TOXNET databases—USEPA’s IRIS database source of oncogenicity and regulatory status information
-Grey literature—Studies submitted to U.S. Environmental Protection Agency that are not published—i.e. industry generated
oncogenicity studies
-Some abstracts of cancer bioassays are on line (IRIS database)
-Request reports from industry
-Request reports from USEPA through Freedom of Information Act
The critical evaluation includes some general background information, including chemical name, CAS#, trade name, history of use ,
and current regulatory status.
Evidence of cancer in other (non-breast) organ systems is provided in synopsis form with some critical commentary, along with the
current overall carcinogenicity classification by international (IARC) and U.S. Federal Agencies (NTP, USEPA).
Human epidemiological studies, animal studies, and other relevant studies on possible mechanisms of carcinogenesis are critically
evaluated for evidence of exposure to agent and breast cancer risk based on “strength of evidence” approach, according to a modification
of IARC criteria as listed in the IARC Preamble (See attached sheets for a more detailed explanation of the BCERF Cancer Risk
classification scheme).
The emphasis of the document is a critical evaluation of the evidence for breast cancer risk, classification of the agent’s breast cancer
risk, identification of research gaps, and recommendations for future studies.  A section is devoted to brief summaries of new research
studies that are in progress.  A bibliography with all cited literature is included in each Critical Evaluation.  Major international, federal
and state agencies will be provided with copies of our report.
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F. CAS # (Chemical Abstract Subject Number)
G. Major Metabolite(s)
II. History of Use, Usage and Nomenclature
A. Date of first registration
B. Uses
C. Past Usage / If available, current usage levels in US and NYS
III. Current Regulatory Status
A. Current Regulatory Status, EPA
B. Drinking Water Standards and Health Advisories
C. Food Residue Tolerances and Action Levels
D. Workplace Regulations (when applicable)
IV. Summary of Evidence of Overall Carcinogenicity (non-breast sites)
A. Human Studies
B. Animal Studies
C. Current Classification of Carcinogenicity by other Agencies
1. IARC (International Agency for Research on Cancer)
2. NTP (National Toxicology Program)
3. USEPA (Environmental Protection Agency)
V. Critical Evaluation of the Scientific Evidence for Breast Cancer Risk
A. Humans Studies will include:
1. Case-Studies
2. Human Epidemiological Cohort Studies
3. Human Epidemiological Case-Control Studies
4. When available will summarize information on detection/accumulation in human tissues/and validation of biomarkers
B. Experimental Animal Studies
C. Other Relevant Information, including mechanisms by which exposure may affect breast cancer risk (examples:
co-carcinogenicity, tumor promotion estrogenicity, endocrine disruption, reproductive toxicology, mutagenicity,
cell proliferation, oncogene/tumor suppressor gene expression, immune function, etc.)
VI. Other Relevant Information
A. Specific for the pesticide; (i.e. may include information on environmental fate, potential for human exposure)
VII. Summary, Conclusions, Recommendation for Breast Cancer Risk Classification
VIII. Identification of Research Gaps, and Other Recommendations
IX. Brief Summaries of New Human Studies Currently Being Conducted
X. Bibliography
XI. Appendix A. Common Abbreviations, Acronyms and Symbols
XII. Appendix B. Critical Evaluations of Breast Cancer Carcinogenicity
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BCERF Breast Carcinogenicity Classification Scheme-revised
12/97 sms
(adapted from the IARC Preamble by S.M.Snedeker)
Group 1:  Human breast carcinogen; sufficient evidence  of
carcinogenicity to humans is necessary.  Sufficient evidence  is
considered to be evidence that a causal relationship has been
established between exposure to the agent and human breast
cancer.
Group 2A:  Probable breast carcinogen; this category generally
includes agents for which there is 1) limited evidence  of breast
carcinogenicity in humans and sufficient evidence  of mammary
carcinogenicity in experimental animals.  The classification may
also be used when there is 2) limited evidence  of breast
carcinogenicity in humans and strong supporting evidence from
other relevant data, or when there is 3) sufficient evidence  of
mammary carcinogenicity in experimental animals and strong
supporting evidence from other relevant data.
Group 2B:  Possible breast carcinogen; this category generally
includes agents for which there is 1) limited evidence  in humans
in the absence of sufficient evidence  in experimental animals; 2)
inadequate evidence  of carcinogenicity in humans or when human
data is nonexistent but there is sufficient evidence  of
carcinogenicity in experimental animals, 3) inadequate evidence
or no data in humans but with limited evidence  of carcinogenicity
in experimental animals together with supporting evidence from
other relevant data.
Group 2C:  Potential to affect breast cancer risk; this category
includes agents for which there is inadequate or nonexistent
human and animal data, but there is supporting evidence from
other relevant data that identifies a mechanism by which the agent
may affect breast cancer risk.  Examples are, but are not limited
to:  evidence of agent’s estrogenicity, disruption of estrogen
metabolism resulting in potential to affect exposure to estrogen;
evidence of breast tumor promotion, progression or co-
carcinogenicity; increased expression of proto-oncogenes or
oncogenes; evidence of inactivation of tumor suppressor gene
associated with breast cancer; evidence of adverse effect on
immune function; or evidence of a structural similarity to a known
breast carcinogen (structure-activity relationship).
Group 3: Not classifiable as to its breast carcinogenicity to
humans.  Agents are placed in this category when they do not fall
into any other group.
Group 4: Probably not a breast carcinogen in humans:  This
category is used for agents for which there is evidence suggesting
a lack of breast carcinogenicity in human studies and in animal
studies, together with a lack of related evidence which may predict
breast cancer risk. The absence of studies does not constitute
evidence for a lack of breast carcinogenicity.
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Brief Definitions of Sufficient, Limited, and Inadequate Evidence:
(adapted from the IARC Preamble by S.M. Snedeker)
Human Studies:
Sufficient evidence of carcinogenicity in humans:  Must have
established evidence between exposure to the agent and human
breast cancer.  Case-reports are given the least weight in
considering carcinogenicity data in humans—they are suggestive
of a relationship, but by themselves cannot demonstrate causality.
Consistent, case-control studies which have controlled for
confounding factors and have found high relative risks of
developing breast cancer in relation to an identified exposure are
given the most weight in determining a causal relationship.
Limited evidence of breast carcinogenicity in humans:  A
positive association has been observed between exposure to the
agent and breast cancer, but chance, bias or confounding factors
could not be ruled out.
Inadequate evidence of breast carcinogenicity in humans:  The
available studies are of insufficient quality, consistency or
statistical power to permit a conclusion regarding the presence or
absence of a causal association.
Experimental Animal Studies:
Sufficient evidence of breast carcinogenicity in animals:
Evidence of malignant tumors or combination of benign and
malignant tumors in (a) two or more species of animals, (b) or
two or more independent studies in one species carried out at
different times or in different laboratories or under different
protocols.
Limited evidence of breast carcinogenicity in animals: The
studies suggest a carcinogenic effect, but are limited for making
a definitive evaluation because: (a) the evidence of carcinogenicity
is restricted to a single experiment; (b) there are unresolved
questions regarding the adequacy of the design, conduct or
interpretation of the study; or (c) the agent increases the incidence
of only benign neoplasms of lesions of uncertain neoplastic
potential, or of certain neoplasms which may occur spontaneously
in high incidences in certain strains of animals.
Inadequate evidence of breast carcinogenicity in animals:  The
studies cannot be interpreted as showing either the presence or
absence of a carcinogenic effect because of major qualitative or
quantitative limitations.
